Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 7
GLP-1 Drugs and Sleep Apnea
A six-trial meta-analysis linked GLP-1-based therapies to fewer apnea events, but high heterogeneity limits the pooled estimate.
REDEFINE 3: CagriSema Trial Design
REDEFINE 3 has published its CagriSema trial design and baseline cohort, but cardiovascular outcome results remain pending.
Semaglutide dose changes: label context
A community dose-change post cannot tell another reader what to do. Product labels and a prescribing clinician provide the relevant context.
Semaglutide Product Switches and Diarrhea
What Ozempic and Wegovy labels say about diarrhea, why a symptom report cannot prove causation, and when official guidance calls for assessment.
Synthetic Semaglutide vs Wegovy
A 24-week Indian phase 3 trial found Sun Pharma's synthetic semaglutide non-inferior to Wegovy for percentage weight change.
Tirzepatide and Cardiovascular Outcomes
A 2026 meta-analysis found no significant MACE difference versus GLP-1 drugs, with high heterogeneity and mostly observational evidence.
Tirzepatide in Type 1 Diabetes
A matched UK cohort linked tirzepatide use to lower weight, HbA1c and insulin needs in type 1 diabetes, but it was not randomized.
Wegovy Symptoms: What the Label Says
A guide to Wegovy's official adverse-reaction and warning language, and why a forum report cannot diagnose what caused one person's symptoms.
GLP-1 Drugs and Aesthetic Surgery
A 2026 narrative review maps aesthetic-surgery concerns after GLP-1-related weight loss but reports no new trial or proven drug-specific effect.
GLP-1 Obesity Guide for Clinicians
A 2026 practical guide organizes obesity prescribing decisions, but it is not a new trial and does not establish a semaglutide-tirzepatide winner.
Semaglutide in Animal HFpEF Models
Rat and minipig HFpEF models showed cardiac and liver changes without substantial weight loss, but they cannot establish human efficacy.
Semaglutide for MASH: MENA Review
A MENA expert panel interprets semaglutide and resmetirom evidence for MASH, with access and regional data gaps central to adoption.